VASP and Stroke: After multivariate adjustment for previous percutaneous coronary intervention, previous stroke, MPV, hsCRP, left ventricular ejection fraction, and aspartate transaminase, dual antiplatelet therapy remained independently significant in predicting HPR in the LTA and VASP assay.